Q-omics provides the consensus-scored SNX19P3 profile across patient tissues and cancer cell-line models. SNX19P3 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, SNX19P3 is differentially expressed in 6, with the highest sampling consensus in BRCA. Additionally, SNX19P3 RNA expression shows 11,948 significant gene co-expression associations, with the highest sampling consensus in DLBC. Together, these results highlight STAD, BRCA, and DLBC as cancer lineages where SNX19P3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNX19P3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNX19P3 survival associations across molecular data types. SNX19P3 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNX19P3 RNA expression–survival associations across cancer types. High SNX19P3 expression shows unfavorable associations in STAD, OV and LUAD, but favorable associations in PAAD, SKCM and CHOL. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify STAD as the clearest survival context for SNX19P3 RNA expression.
This table summarizes SNX19P3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for SNX19P3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNX19P3 shows lower tumor expression in KIRC and THCA and higher tumor expression in BRCA, LIHC, COAD and STAD. The BRCA box plot shows higher SNX19P3 RNA expression in tumor versus normal tissue (log2 FC = +0.159, t-test p = .004).
This table shows molecular features associated with SNX19P3 in patient tissues and cancer cell lines. In patient samples, SNX19P3 shows the broadest associations at the RNA and protein expression levels, with DLBC recurring as the lineage with the largest associated feature set.
